Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
Public ClinicalTrials.gov record NCT01568866. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study was to compare progression-free survival in patients with multiple myeloma who relapsed after 1 to 3 prior therapies treated with carfilzomib plus dexamethasone or bortezomib plus dexamethasone.
Study identification
- NCT ID
- NCT01568866
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 929 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 20, 2012 (Actual)
- Primary completion
- Nov 10, 2014 (Actual)
- Completion
- Feb 5, 2018 (Actual)
- Last update posted
- Nov 14, 2022
2012 – 2018
United States locations
- U.S. sites
- 27
- U.S. states
- 17
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Providence St. Joseph Medical Center | Burbank | California | — | — |
| UCSD Moore Cancer Center | La Jolla | California | — | — |
| UCLA Medical Center | Los Angeles | California | — | — |
| Central Coast Medical Oncology Group | Santa Maria | California | — | — |
| Colorado Blood Cancer Institute | Denver | Colorado | — | — |
| MAB Oncology/Hematology | Melbourne | Florida | — | — |
| Palm Beach Cancer Institute | West Palm Beach | Florida | — | — |
| Winship Cancer Institute | Atlanta | Georgia | — | — |
| Hematology Oncology of Indiana, PC | Indianapolis | Indiana | — | — |
| Center for Cancer and Blood Disorders | Bethesda | Maryland | — | — |
| Associates in Oncology/Hematology PC | Rockville | Maryland | — | — |
| University of Michigan | Ann Arbor | Michigan | — | — |
| University of Kansas | Kansas City | Missouri | — | — |
| Hackensack University Medical Ctr | Hackensack | New Jersey | — | — |
| Clinical Research Alliance Inc. | New York | New York | — | — |
| Weill Cornell Medical College | New York | New York | — | — |
| Montefiore Medical Center | The Bronx | New York | — | — |
| Wake Forest University Health Sciences, Section on Hematology and Oncology | Winston-Salem | North Carolina | — | — |
| Gabrail Cancer Center | Canton | Ohio | — | — |
| The Christ Hospital | Cincinnati | Ohio | — | — |
| Western Pennsylvania Hospital | Pittsburgh | Pennsylvania | — | — |
| Hematology/Oncology Associates of SC | Greenville | South Carolina | — | — |
| Vanderbilt Ingram Cancer Center | Nashville | Tennessee | — | — |
| MD Anderson | Houston | Texas | — | — |
| The Methodist Cancer Center | Houston | Texas | — | — |
| Scott & White Memorial Hospital | Temple | Texas | — | — |
| University of Utah School of Medicine | Salt Lake City | Utah | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 214 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01568866, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 14, 2022 · Synced Nov 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01568866 live on ClinicalTrials.gov.